GSK Buys Back Own Shares
Ticker: GLAXF · Form: 6-K · Filed: Apr 10, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Apr 10, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-repurchase, stock-buyback
TL;DR
GSK is buying back its own stock via Citigroup.
AI Summary
GSK plc announced on April 10, 2025, that it has purchased a number of its own ordinary shares. The transactions were executed through its corporate stockbroker, Citigroup Global Markets Limited. The filing does not specify the exact number of shares or the total dollar amount involved in these share repurchases.
Why It Matters
Share buybacks can signal management's confidence in the company's valuation and potentially increase earnings per share.
Risk Assessment
Risk Level: low — This is a routine filing reporting on share repurchases, with no immediate negative or positive financial implications disclosed.
Key Players & Entities
- GSK plc (company) — Registrant
- Citigroup Global Markets Limited (company) — Corporate stockbroker executing share purchases
- April 10, 2025 (date) — Date of announcement and transaction
FAQ
What is the purpose of this Form 6-K filing?
This Form 6-K filing reports on GSK plc's transactions in its own shares.
Who is acting as GSK's stockbroker for these transactions?
Citigroup Global Markets Limited is acting as GSK's corporate stockbroker.
On what date did GSK announce these share repurchases?
GSK announced these share repurchases on April 10, 2025.
Does the filing specify the number of shares GSK purchased?
No, the filing states that GSK has purchased 'the following number of the Company's ordinary shares' but the specific number is not detailed in the provided text.
What is the par value of GSK's ordinary shares mentioned in the filing?
The par value of GSK's ordinary shares is 31¼ pence each.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 10, 2025 regarding GSK plc (GLAXF).